ICES-13

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameICES-13

Drug Alias NameSMDCsSkeletal muscle-derived cellsICES-13

ClassificationCell and gene therapy > Cell therapy > Somatic cell > Myoblast therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Skeletal muscle-derived

Mechanisms of ActionCell replacementsCells stimulants

TargetsNot applicable

Therapy Area/IndicationsUrinary Incontinence, StressFecal Incontinence

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBulgariaSweden +[12]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesInnovacell Biotechnologie Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesInnovacell Ag

Inactive CompaniesLjubljana University Medical Centre

Active IndicationsFecal Incontinence

Inactive IndicationsUrinary Incontinence, Stress

Other Information

ATC CodeN/A